Enzymatically Active ADAMTS13 Variants Are Not Inhibited by Anti-ADAMTS13 Autoantibodies
Open Access
- 1 December 2005
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (48), 39934-39941
- https://doi.org/10.1074/jbc.m504919200
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpuraThrombosis and Haemostasis, 2005
- Molecular Mechanisms in Thrombotic Thrombocytopenic PurpuraSeminars in Thrombosis and Hemostasis, 2004
- An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutationsThrombosis and Haemostasis, 2004
- Shear Stress and von Willebrand Factor in Health and DiseaseSeminars in Thrombosis and Hemostasis, 2003
- Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndromeBlood, 2003
- ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activityBlood, 2003
- Mutation analysis and clinical implications of von Willebrand factor–cleaving protease deficiencyKidney International, 2003
- von Willebrand factor cleaving protease and ADAMTS13mutations in childhood TTPBlood, 2003
- ADAMTS 13 genotype and vWF protease activity in an Italian family with TTPThrombosis and Haemostasis, 2003
- Von Willebrand factor–cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpuraBlood, 2002